ESSA Pharma Management

Management criteria checks 4/4

ESSA Pharma's CEO is David Parkinson, appointed in Jan 2016, has a tenure of 8.25 years. total yearly compensation is $814.15K, comprised of 70.9% salary and 29.1% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $420.89K. The average tenure of the management team and the board of directors is 8 years and 4.8 years respectively.

Key information

David Parkinson

Chief executive officer

US$814.2k

Total compensation

CEO salary percentage	70.9%
CEO tenure	8.3yrs
CEO ownership	0.1%
Management average tenure	8yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Parkinson's remuneration changed compared to ESSA Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$26m
Sep 30 2023	US$814k	US$578k	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	n/a	n/a	-US$33m
Sep 30 2022	US$922k	US$549k	-US$35m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	n/a	n/a	-US$39m
Sep 30 2021	US$2m	US$518k	-US$37m
Jun 30 2021	n/a	n/a	-US$33m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	n/a	n/a	-US$25m
Sep 30 2020	US$3m	US$492k	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	n/a	n/a	-US$15m
Sep 30 2019	US$996k	US$469k	-US$13m
Jun 30 2019	n/a	n/a	-US$12m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	n/a	n/a	-US$12m
Sep 30 2018	US$1m	US$446k	-US$12m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	n/a	n/a	-US$8m
Sep 30 2017	US$964k	US$436k	-US$4m

Compensation vs Market: David's total compensation ($USD814.15K) is below average for companies of similar size in the US market ($USD1.60M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Parkinson (73 yo)

8.3yrs

Tenure

US$814,152

Compensation

Dr. David Ross Parkinson, M.D., has been a Director of Realm Therapeutics plc. since July 31, 2019. He serves as Member of Advisory Board at AsedaSciences Inc. Dr. Parkinson had been an Independent Directo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Parkinson	President	8.3yrs	US$814.15k	0.15% $ 420.9k
David Wood	Chief Financial Officer	10.8yrs	US$590.39k	0.075% $ 213.4k
Peter Virsik	Executive VP & COO	7.7yrs	US$645.95k	0.027% $ 76.4k
Alessandra Cesano	Chief Medical Officer & Executive VP	4.8yrs	US$623.93k	0.012% $ 32.8k
Chandtip Chandhasin	Executive	no data	no data	no data
Erica Osbourne	Executive	no data	no data	no data
Erin Rudsinski	Executive	no data	no data	no data
Loleta Harris	Executive	no data	no data	no data
Neil Thapar	Executive	no data	no data	no data
Nkengyal Barber	Executive	no data	no data	no data
Steve Pondell	Executive	no data	no data	no data
Terry Schuenemeyer	Executive	no data	no data	no data

8.0yrs

Average Tenure

64yo

Average Age

Experienced Management: EPIX's management team is seasoned and experienced (8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Parkinson	President	8.8yrs	US$814.15k	0.15% $ 420.9k
Sanford Zweifach	Independent Director	4.8yrs	US$48.00k	0% $ 0
Richard Glickman	Independent Chairman of the Board	13.5yrs	US$70.00k	0.11% $ 306.9k
Gary Sollis	Independent Director	12yrs	US$50.00k	0% $ 0
John Martin	Independent Director	4.8yrs	US$35.00k	0.032% $ 91.5k
Franklin Berger	Independent Director	9.1yrs	US$54.00k	1.77% $ 5.0m
Scott Requadt	Independent Director	8.3yrs	US$47.00k	0.068% $ 192.0k
Philip Kantoff	Independent Director	1.6yrs	US$35.00k	0% $ 0
Marella Thorell	Independent Director	4.8yrs	US$42.00k	0.0065% $ 18.4k
Marianne Sadar	Scientific Advisor	4.8yrs	US$229.20k	no data
Raymond Andersen	Scientific Advisor	no data	US$229.20k	no data
Lauren Merendino	Independent Director	less than a year	US$162.67k	0% $ 0

4.8yrs

Average Tenure

66yo

Average Age

Experienced Board: EPIX's board of directors are considered experienced (4.8 years average tenure).

ESSA Pharma Management

Management criteria checks 4/4

Key information

Recent management updates

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

Independent Director recently bought US$135k worth of stock

Independent Director recently bought US$420k worth of stock

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Independent Director notifies of intention to sell stock

Recent updates

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

New major risk - Revenue and earnings growth

Independent Director recently bought US$135k worth of stock

New major risk - Share price stability

Independent Director recently bought US$420k worth of stock

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Now 21% undervalued after recent price drop

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Now 23% undervalued

Independent Director notifies of intention to sell stock

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2023

ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen

Insufficient new directors

ESSA Pharma Inc. Announces Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Appoints Philip Kantoff to its Board of Directors

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

ESSA Pharma Inc. Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients

ESSA Pharma Inc. Enters into Clinical Collaboration and Supply Agreement with Astellas Pharma Inc. to Evaluate Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. has completed a Follow-on Equity Offering in the amount of $130.434786 million.

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

ESSA Pharma EPS beats by $0.02

ESSA Pharma Inc. Announces Voluntary Delisting from the TSX-V

New 90-day low: US$6.10

Independent Chairman of the Board recently bought US$37k worth of stock

Essa Pharma Inc. Announces the Presentation of Data of ESSA's Clinical Candidate, EPI-7386, at the ESMO Virtual Congress 2020

New 90-day high - US$7.64

Independent Director recently bought US$551k worth of stock

New 90-day high - US$7.06

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age